News headlines about Intra-Cellular Therapies (NASDAQ:ITCI) have been trending somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Intra-Cellular Therapies earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.1739612101332 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Intra-Cellular Therapies Inc (ITCI) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Intra-Cellular Therapies (ITCI) Lifted to Buy at BidaskClub (americanbankingnews.com)
- Focus on 52-week high Stock – Intra-Cellular Therapies, Inc. (ITCI) – The Stocks News (press release) (thestocksnews.com)
- Intra-Cellular Therapies, Inc. (ITCI)- Price to Earnings Ratio under Consideration – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Brief Overview on Stock’s Performances – Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) – The Investor Guide (wallstreetnews24.com)
Intra-Cellular Therapies (ITCI) opened at $23.98 on Friday. The company has a market capitalization of $1,365.37, a P/E ratio of -11.31 and a beta of 0.66. Intra-Cellular Therapies has a 1 year low of $7.85 and a 1 year high of $25.82.
ITCI has been the topic of several recent analyst reports. Zacks Investment Research downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. ValuEngine downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 5th. BidaskClub downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 12th. Finally, Canaccord Genuity initiated coverage on Intra-Cellular Therapies in a research report on Friday, December 15th. They issued a “buy” rating and a $31.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $27.09.
In other news, Chairman Sharon Mates sold 11,257 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $17.08, for a total transaction of $192,269.56. Following the sale, the chairman now directly owns 1,099,964 shares in the company, valued at $18,787,385.12. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Lawrence J. Hineline sold 49,700 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $20.02, for a total value of $994,994.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 98,210 shares of company stock worth $1,846,548. 19.80% of the stock is currently owned by company insiders.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.